Upsurge in collaboration between pharmaceutical companies for drug development and surge in prevalence of chronic diseases are the key factors that augment the growth of the global oral proteins and peptides market. Moreover, rise in geriatric population and improvement in healthcare infrastructure are expected to boost the market growth.
However, low bioavailability of oral proteins and peptides and high cost associated with drug development are some of the factors that restrain the market growth. Conversely, increase in purchasing power of developing countries and rise in R&D activities by pharmaceutical companies are expected to provide new opportunities for market players in the near future.
The oral proteins and peptides market is segmented into drug type, application, and region. By drug type, the market is divided into linaclotide, plecanatide, calcitonin, insulin, and octreotide. By application, it is categorized into gastric & digestive disorders, bone diseases, diabetes, and hormonal disorders. Based on region, it is analyzed across the U.S. and rest of the world.
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis of the current market trends and future estimations from 2016 to 2028 to identify the prevailing opportunities.
The oral proteins and peptides market size and estimations are based on comprehensive analysis of the key developments in the industry.
In-depth analysis based on region assists to understand the regional market and the strategic business planning.
The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Drug Type
Gastric & Digestive Disorders
Rest of the world
The list of key players operating in this market includes:
Proxima Concepts Limited (Diabetology Ltd.)
Generex Biotechnology Corp.
Novo Nordisk A/S
Synergy Pharmaceuticals Inc.
Tarsa Therapeutics Inc.
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Clinical trials
3.4. Top player positioning, 2018
3.5. Patent analysis, 2010-2017
3.5.1. Patent analysis, by year (2010-2017)
3.5.2. Patent analysis, by country
3.6. Market dynamics
220.127.116.11. Increase in collaboration between pharmaceutical companies for drug development
18.104.22.168. Surge in prevalence of chronic diseases
22.214.171.124. Rise in geriatric population and improvement in healthcare infrastructure
126.96.36.199. Low bioavailability of oral proteins and peptides
188.8.131.52. High costs associated with drug development
184.108.40.206. Increase in purchasing power of emerging economics
220.127.116.11. Increase in R&D activities by pharmaceutical companies
CHAPTER 4: ORAL PROTEINS AND PEPTIDES MARKET, BY DRUG TYPE
4.1.1. Market size and forecast
4.2.1. Key market trends
4.2.2. Market size and forecast
4.3.1. Key market trends
4.3.2. Market size and forecast
4.4.1. Key market trends
4.4.2. Market size and forecast
4.5.1. Key market trends
4.5.2. Market size and forecast
4.6.1. Key market trends
4.6.2. Market size and forecast
CHAPTER 5: ORAL PROTEINS AND PEPTIDES MARKET, BY APPLICATION
5.1.1. Market size and forecast
5.2. Gastric & digestive disorders
5.2.1. Market size and forecast
5.3. Bone diseases
5.3.1. Market size and forecast
5.4.1. Market size and forecast
5.5. Hormonal disorders
5.5.1. Market size and forecast
CHAPTER 6: ORAL PROTEINS AND PEPTIDES MARKET, BY REGION
6.1.1. Market size and forecast
6.2.1. Key market trends
6.2.2. Market size and forecast
6.3. Rest of the world
6.3.1. Key market trends
6.3.2. Market size and forecast
CHAPTER 7: COMPANY PROFILES
7.1. Allergan Plc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. AstraZeneca PLC
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Product portfolio
7.2.4. Business performance
7.2.5. Key strategic moves and developments
7.3. Biocon Limited
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. Chiasma Inc.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Product portfolio
7.4.4. Key strategic moves and developments
7.5. Generex Biotechnology Corp.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Key strategic moves and developments
7.6. Novo Nordisk A/S
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Oramed Pharmaceuticals Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Product portfolio
7.7.4. Key strategic moves and developments
7.8. Proxima Concepts Limited (Diabetology Ltd.)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.9. Synergy Pharmaceuticals Inc.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Product portfolio
7.9.4. Key strategic moves and developments
7.10. Tarsa Therapeutics Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Product portfolio
7.10.4. Key strategic moves and developments
Therapeutic proteins and peptides are an important class of drugs, which serve patients in need of novel therapies. Approved oral proteins and peptides drugs are indicated to treat a wide array of clinical indications, including diabetes, gastric & metabolic disorders, and hormonal disorders.
The major factors that drive the growth of the global oral proteins and peptides market include increase in collaborative efforts between pharmaceutical companies, surge in prevalence of chronic conditions, increase in elderly population, and rise in awareness & preference among populace for oral proteins and peptide-based drugs.
However, high cost associated with drug development and low bioavailability of these drugs impede the market growth. Conversely, increase in novel indications for known oral protein therapeutics, high R&D investment by pharmaceutical companies in oral proteins & peptides drugs, and rise in purchasing power in the emerging markets are anticipated to provide lucrative opportunities for the manufacturers in this industry.
The gastric & digestive disorders application generated the highest revenue in 2016, and is anticipated to continue this trend in the future. This is attributed to the approval and high adoption of oral proteins and peptide drugsLINZESS (Allergan, Inc.) and TRULANCE (Synergy Pharmaceuticals, Inc.). The diabetes application is anticipated to grow at the highest CAGR of 13.4% from 2022 to 2028.
The U.S. held the highest market share in 2016, owing to high prevalence rate of chronic diseases, rise in adoption of these drugs, and increase in awareness about oral protein and peptide therapeutics. The rest of the world is expected to grow owing to rapid industrialization, increase in disposable income, and upsurge in government initiatives to modernize healthcare infrastructure.
Key findings of the Oral Proteins And Peptides Market:
The insulin drug type segment is anticipated to grow at the highest CAGR from 2022 to 2028
The gastric & digestive disorder application segment is anticipated to occupy the largest share in the oral proteins and peptides market
The diabetes segment is expected to witness the highest growth rate during the forecast period
The U.S. dominated the oral proteins and peptides market, and is projected to grow at a CAGR of 11.7%
The report provides extensive competitive analysis and profiles of key market players, such as Allergan plc, AstraZeneca plc, Biocon Limited, Chiasma, Inc., Proxima Concepts Limited (Diabetology Ltd.), Generex Biotechnology Corp., Novo Nordisk A/S, Synergy Pharmaceuticals Inc., and Tarsa Therapeutics Inc. Other players (profiles not included in the report) in the value chain analysis include Sanofi S.A., F. Hoffmann-La Roche AG, Synthetic Biologics, Inc., Hovione Limited, and Novartis International AG.